424 related articles for article (PubMed ID: 15767856)
1. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia.
Maxwell KN; Breslow JL
Curr Opin Lipidol; 2005 Apr; 16(2):167-72. PubMed ID: 15767856
[TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.
Ouguerram K; Chetiveaux M; Zair Y; Costet P; Abifadel M; Varret M; Boileau C; Magot T; Krempf M
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1448-53. PubMed ID: 15166014
[TBL] [Abstract][Full Text] [Related]
4. PCSK9 and LDL cholesterol: unravelling the target to design the bullet.
Costet P; Krempf M; Cariou B
Trends Biochem Sci; 2008 Sep; 33(9):426-34. PubMed ID: 18672372
[TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.
Awan Z; Baass A; Genest J
Clin Chem; 2014 Nov; 60(11):1380-9. PubMed ID: 25248569
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
Abifadel M; Guerin M; Benjannet S; Rabès JP; Le Goff W; Julia Z; Hamelin J; Carreau V; Varret M; Bruckert E; Tosolini L; Meilhac O; Couvert P; Bonnefont-Rousselot D; Chapman J; Carrié A; Michel JB; Prat A; Seidah NG; Boileau C
Atherosclerosis; 2012 Aug; 223(2):394-400. PubMed ID: 22683120
[TBL] [Abstract][Full Text] [Related]
7. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Abifadel M; Varret M; Rabès JP; Allard D; Ouguerram K; Devillers M; Cruaud C; Benjannet S; Wickham L; Erlich D; Derré A; Villéger L; Farnier M; Beucler I; Bruckert E; Chambaz J; Chanu B; Lecerf JM; Luc G; Moulin P; Weissenbach J; Prat A; Krempf M; Junien C; Seidah NG; Boileau C
Nat Genet; 2003 Jun; 34(2):154-6. PubMed ID: 12730697
[TBL] [Abstract][Full Text] [Related]
8. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
Tibolla G; Norata GD; Artali R; Meneghetti F; Catapano AL
Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):835-43. PubMed ID: 21943799
[TBL] [Abstract][Full Text] [Related]
9. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.
Lin J; Wang LY; Liu S; Wang XM; Yong Q; Yang Y; DU LP; Pan XD; Wang X; Jiang ZS
Chin Med J (Engl); 2010 May; 123(9):1133-8. PubMed ID: 20529551
[TBL] [Abstract][Full Text] [Related]
10. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.
Mabuchi H; Nohara A; Noguchi T; Kobayashi J; Kawashiri MA; Inoue T; Mori M; Tada H; Nakanishi C; Yagi K; Yamagishi M; Ueda K; Takegoshi T; Miyamoto S; Inazu A; Koizumi J;
Atherosclerosis; 2014 Sep; 236(1):54-61. PubMed ID: 25014035
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
12. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
[TBL] [Abstract][Full Text] [Related]
13. Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.
Si-Tayeb K; Idriss S; Champon B; Caillaud A; Pichelin M; Arnaud L; Lemarchand P; Le May C; Zibara K; Cariou B
Dis Model Mech; 2016 Jan; 9(1):81-90. PubMed ID: 26586530
[TBL] [Abstract][Full Text] [Related]
14. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
Schiele F; Park J; Redemann N; Luippold G; Nar H
J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
[TBL] [Abstract][Full Text] [Related]
15. No genetic linkage or molecular evidence for involvement of the PCSK9, ARH or CYP7A1 genes in the Familial Hypercholesterolemia phenotype in a sample of Danish families without pathogenic mutations in the LDL receptor and apoB genes.
Damgaard D; Jensen JM; Larsen ML; Soerensen VR; Jensen HK; Gregersen N; Jensen LG; Faergeman O
Atherosclerosis; 2004 Dec; 177(2):415-22. PubMed ID: 15530918
[TBL] [Abstract][Full Text] [Related]
16. PCSK9: a key modulator of cardiovascular health.
Seidah NG; Awan Z; Chrétien M; Mbikay M
Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727
[TBL] [Abstract][Full Text] [Related]
17. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
18. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I
Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133
[TBL] [Abstract][Full Text] [Related]
19. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.
Abifadel M; Rabès JP; Devillers M; Munnich A; Erlich D; Junien C; Varret M; Boileau C
Hum Mutat; 2009 Apr; 30(4):520-9. PubMed ID: 19191301
[TBL] [Abstract][Full Text] [Related]
20. How does mutant proprotein convertase neural apoptosis-regulated convertase 1 induce autosomal dominant hypercholesterolemia?
Jirholt P; Adiels M; Borén J
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1334-6. PubMed ID: 15297286
[No Abstract] [Full Text] [Related]
[Next] [New Search]